|
Feb 18, 2026
|
|
LONG
|
Makary notes that GLP-1 shortages are ending and emphasizes that compounders should be getting APIs directly from the patent holders (Novo Nordisk and Eli Lilly) to "play by the rules." The regulatory crackdown on "grey market" compounders eliminates low-cost competition. As the FDA forces the market back toward approved products and authorized supply chains, volume and pricing power return to the IP owners. LONG as the regulatory moat is re-established. Continued supply chain constraints or political pressure on list prices. |
CNBC
FDA's Marty Makary: Everything should be over...
|
|
Feb 18, 2026
|
|
AVOID
|
Makary defends the FDA's "refusal to file" decision on Moderna's flu vaccine, stating the trial used "substandard of care" (no flu shot) for the control group of seniors, rather than the existing effective flu shot. This indicates the FDA will hold mRNA platforms to rigorous traditional standards rather than granting the emergency leeway seen during COVID. It signals delays and higher hurdles for Moderna's non-COVID pipeline. AVOID until regulatory pathway clarifies. Moderna could rapidly redesign trials or produce overwhelming data that satisfies the FDA. |
CNBC
FDA's Marty Makary: Everything should be over...
|
|
Feb 18, 2026
|
|
SHORT
|
Makary describes PBM "spread pricing" (where PBMs mark up drugs significantly) as a "money game" and "price gouging" that the administration "is not going to stand for." The FDA and administration are explicitly targeting the opaque profit margins of PBMs (like CVS Caremark, Optum, Express Scripts) to lower drug costs. This policy shift threatens their core profitability. SHORT the sector (CVS / CI / UNH) on regulatory headwinds. Lobbying efforts may dilute actual policy implementation. |
CNBC
FDA's Marty Makary: Everything should be over...
|
|
Feb 18, 2026
|
|
LONG
|
The FDA aims to cut the "pre-IND" approval timeline from 520 days down to competitive levels (China is ~200 days) to bring Phase 1 trials back to the US. Reducing regulatory red tape and startup time for clinical trials lowers cash burn for early-stage biotechs and encourages domestic innovation. LONG the US biotech ecosystem. Bureaucratic inertia may prevent meaningful process changes. |
CNBC
FDA's Marty Makary: Everything should be over...
|
|
Feb 18, 2026
|
|
SHORT
|
Makary explicitly confirms the FDA sent Hims & Hers a warning letter in September regarding their marketing claims and compounding practices. He states the FDA is "serious about cracking down on mass marketing claims" and unapproved APIs now that shortages are ending. HIMS has relied heavily on compounded GLP-1s for recent growth. An active FDA crackdown targeting them by name suggests significant regulatory risk to this revenue stream. SHORT due to heightened regulatory enforcement and the end of the shortage exemptions that allowed their business model to thrive. HIMS may successfully pivot to branded partnerships or the FDA enforcement may be slower than anticipated. |
CNBC
FDA's Marty Makary: Everything should be over...
|